125 related articles for article (PubMed ID: 2513429)
21. The effect of three novel thromboxane A2 receptor antagonists (S-1452, AA-2414 and ONO-3708) on the increase in pulmonary pressure caused by Forssman anaphylaxis in guinea-pigs.
Nagai H; Kumimoto M; Yoshitake K; Iwama T; Arimura A; Koda A
Prostaglandins Leukot Essent Fatty Acids; 1992 Mar; 45(3):233-8. PubMed ID: 1534171
[TBL] [Abstract][Full Text] [Related]
22. G619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, reduces myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion in rats.
Squadrito F; Ioculano M; Altavilla D; Zingarelli B; Canale P; Campo GM; Saitta A; Oriti S; Spignoli G; Caputi AP
Pharmacology; 1993 Sep; 47(3):167-75. PubMed ID: 8415867
[TBL] [Abstract][Full Text] [Related]
23. TxA2 inhibition and ischemia-induced loss of myocardial function and reactive hyperemia.
Mehta JL; Nichols WW; Schofield R; Donnelly WH; Chandna VK
Am J Physiol; 1990 May; 258(5 Pt 2):H1402-8. PubMed ID: 2159727
[TBL] [Abstract][Full Text] [Related]
24. Effect of a novel thromboxane A2 synthetase inhibitor on ischemia-induced mitochondrial dysfunction in canine hearts.
Ogawa T; Hieda N; Sugiyama S; Toki Y; Ito T; Ogawa K; Satake T; Ozawa T
Arzneimittelforschung; 1988 Feb; 38(2):228-30. PubMed ID: 3370069
[TBL] [Abstract][Full Text] [Related]
25. Leukotriene antagonists attenuate thromboxane-inducible pulmonary hypertension.
Soifer SJ; Schreiber MD; Heymann MA
Pediatr Res; 1989 Aug; 26(2):83-7. PubMed ID: 2505220
[TBL] [Abstract][Full Text] [Related]
26. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
[TBL] [Abstract][Full Text] [Related]
27. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
[TBL] [Abstract][Full Text] [Related]
28. Effects of thromboxane synthetase inhibitor (RS-5186) on experimentally-induced cerebral vasospasm.
Takeuchi H; Tanabe M; Okamoto H; Yamazaki M
Neurol Res; 1999 Jul; 21(5):513-6. PubMed ID: 10439434
[TBL] [Abstract][Full Text] [Related]
29. Reduction in myocardial neutrophil accumulation and infarct size following administration of thromboxane inhibitor U-63,557A.
Wargovich TJ; Mehta J; Nichols WW; Ward MB; Lawson D; Franzini D; Conti CR
Am Heart J; 1987 Nov; 114(5):1078-85. PubMed ID: 2960223
[TBL] [Abstract][Full Text] [Related]
30. Effects of 5-lipoxygenase inhibition on cardiac anaphylaxis in isolated guinea pig hearts.
Jolly SR; Travis J; Van Inwegen RG
Pharmacology; 1989; 38(6):352-62. PubMed ID: 2813496
[TBL] [Abstract][Full Text] [Related]
31. Effect of the thromboxane receptor antagonist SQ 29,548 on myocardial infarct size in dogs.
Grover GJ; Schumacher WA
J Cardiovasc Pharmacol; 1988 Jan; 11(1):29-35. PubMed ID: 2450253
[TBL] [Abstract][Full Text] [Related]
32. Lack of thromboxane A2 involvement in the arrhythmias occurring during acute myocardial ischemia in dogs.
Burke SE; Antonaccio MJ; Lefer AM
Basic Res Cardiol; 1982; 77(4):411-22. PubMed ID: 6890805
[TBL] [Abstract][Full Text] [Related]
33. Possible role of thromboxane A2 in remote hind limb preconditioning-induced cardioprotection.
Sharma R; Randhawa PK; Singh N; Jaggi AS
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jan; 389(1):1-9. PubMed ID: 26531833
[TBL] [Abstract][Full Text] [Related]
34. Tissue-type plasminogen activator alone or in combination with thromboxane A2 synthetase inhibitor for ischemic myocardium.
Ogawa T; Miura T; Tsuchida A; Iwamoto T; Urabe K; Endoh A; Iimura O
Can J Cardiol; 1990 Oct; 6(8):361-6. PubMed ID: 2125235
[TBL] [Abstract][Full Text] [Related]
35. Lack of involvement of thromboxane A2 in postischemic recovery of stunned canine myocardium.
Farber NE; Pieper GM; Gross GJ
Circulation; 1988 Aug; 78(2):450-61. PubMed ID: 3396181
[TBL] [Abstract][Full Text] [Related]
36. Thromboxane A2 does not contribute to arrhythmogenesis during evolving canine myocardial infarction.
Kramer JB; Davis AG; Dean R; McCluskey ER; Needleman P; Corr PB
J Cardiovasc Pharmacol; 1985; 7(6):1069-76. PubMed ID: 2418290
[TBL] [Abstract][Full Text] [Related]
37. Thromboxane synthetase inhibition with CGS 13080 improves coronary blood flow after streptokinase-induced thrombolysis.
Mickelson JK; Simpson PJ; Gallas MT; Lucchesi BR
Am Heart J; 1987 Jun; 113(6):1345-52. PubMed ID: 3591602
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of thromboxane A2 activity during warm ischemia of the liver.
Shirabe K; Kin S; Shinagawa Y; Chen S; Payne WD; Sugimachi K
J Surg Res; 1996 Feb; 61(1):103-7. PubMed ID: 8769950
[TBL] [Abstract][Full Text] [Related]
39. Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma.
Obase Y; Shimoda T; Matsuo N; Matsuse H; Asai S; Kohno S
Chest; 1998 Oct; 114(4):1028-32. PubMed ID: 9792572
[TBL] [Abstract][Full Text] [Related]
40. Myocardial salvage induced by REV-5901: an inhibitor and antagonist of the leukotrienes.
Mullane K; Hatala MA; Kraemer R; Sessa W; Westlin W
J Cardiovasc Pharmacol; 1987 Oct; 10(4):398-406. PubMed ID: 2444792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
